Target Nanoparticles for Cancer Therapy : Structure Investigation by SAXS, SANS, ASAXS, DLS and Electron Microscopy

"Dynamical Ph In Soft Matter" ··enomena * - Worksho ESRF User Meeting 2006 Grenoble, 7.-9-2-2006 823 insd de nawroth@mpsd.de

T. Nawroth¹, Ch. Meesters², H. Decker², M. Rusp³, R.P. May⁴, P. Boesecke⁵

¹ Biochemistry Institute, Becherweg 30, Gutenberg-University, D-55099 Mainz & FerroMed, Germany

- ² Molecular Biophysics Institute, Welderweg 23, Gutenberg-University, D-55099 Mainz, Germany
- ³ Biophysics Institute E22, James-Franck-Straße, TU-Munich, D-85375 Garching, Germany
- ⁴ ILL, Large Scale Structure Group LSS, BP156, Avenue des Martyrs, F-38042 Grenoble Cedex, France ⁵ ESRF, Beamline ID1, BP220, Rue Jules Horowitz, F-38043 Grenoble Cedex, France

Therapy of cancer and specific imaging can be extended by indirect radiation therapy IRT using heavy metal targets with synchrotron X-ray radiation, as shown in figure 1, or neutrons (Gd)

In our concept the ratio of healing to radiation damage effects is improved with magnetic target nanoparticles which are based on two principles (figures 1):

concentration of about 1000,000 target atoms in nanoparticles

- local enrichment of the nanoparticles by magnetic forces at the tumor site

We use two kinds of magnetic target nanoparticles shown in fig.2: i) magnetic target liposomes, which bear the water soluble target in the entrapped lumen, and ii) double shell poly-Ferrofluids, containing the target bound in a surface layer. Our target nanoparticles are biocompatible. The heavy metal is applied as stable metal-DTPA complex, e.g. Lutetium-DTPA, Gd-DTPA (no metabolism; Gd-DTPA is usual in MRI (2g)).

The magnetic target nanoparticles and their components were characterized by various methods, due to the wide size distribution of the components (5 nm – 1 μ m) and variing chemical composition and scattering.

- size distribution and structure of poly-Ferrofluids and magnetite cores were obtained by DLS, SAXS (ID1)

- structure and magnetic superstructure were characterized by electron microscopy and magnetic DLS - magnetic moments of poly-Ferrofluids and γ-Fe₂O₃ cores were investigated with a magnetic balance

- structure dynamics of magnetic shell liposomes (fig.2c) and liposomes was studied by SANS at ILL-D22

- magnetic liposomes with metal targets were analyzed by ASAXS at the L-edge of absorption at ESRF-ID1 - medical applications and imaging were done at the K-edge of absoption (50-80 keV) at ESRF-ID17



TR-SANS time-resolved neutron scattering of magnetic liposomes



XS – ASAXS - XAS of magnetic target liposomes & poly- Ferrofluids

0.00

0.007



flat layer of 0.05 - 10 mm path)

Fig.9: Thin layer cell for ASAXS of fluids at ESRF-ID1 (adjustable

Fig.10: XAS of magnetic shell liposomes with entrapped Gd-target (fig2c, 5c) during ASAXS at ESRF-ID1 (MD118)

7.25 [keV] Fig.11: XAS of Gd-target during ASAXS of liposomes (ESRF-ID1)

References :

Gd-citrat 0.222 M

Magnetic superstructure during therapy conditions : M-DLS & M-EM



Fig.14: Magnetic dynamic light scattering M-DLS of a shell poly-Ferrofluid at 15 mT reversible formation of a µm-sized magnetic superstructure, which is the structure persent during therapy





Fig.1: Nanotherapy improves the effect of molecular active substances (drug, target) twice ~1,000,000 molecules are concentrated in nanoparticles, which are enriched at the tumor locally



Fig.2: Magnetic and target entities (T) for nanotherapy can be introduced in magnetic liposomes (a-c: metal-lipd, entrapped core, double-shell liposomes), or in double-shell poly-Ferrofluids (d).



Fig.5: Non-stained electron micrographs of magnetic nanoparticles (metal images) : magnetic liposomes (a-c: metal-lipd, entrapped core, double-shell liposomes), disk-shaped poly-Ferrofluids (d).

The structure of target nanoparticles have for the medical application to fulfill critical demands:

1) The structure has to be smaller than 500 nm, because of embolic risks (blocking blood capillaries); 2) The particle shape has to be free of cell demaging edges;

3) The particle entrapped target volume & concentration has to be sufficient for radiation therapy; Metallo-liposomes containing a metal lipid (DTPA-DMPE + Eu, Tb, Gd) shown in fig2a, 5a, as

studied by EM and ASAXS at ESRF-ID1 (LS1554, 1718, 1843), were homogenous spheres (45 nm) but contained only 0.4 mM target metal bound outside (liposome post sonication lanthanide-loading).

The double layer magnetic liposmes containing an inner magnetite/ maghemite and an outer lipid layer [1] were investigated by time resolved neutron scattering TR-SANS at ILL-D22 during preparation (y-Fe2O3-deposition), as shown in fig.6-8. Optimized liposomes of 250 nm size were target loaded [3] with Boron-diol esters for neutron capture therapy (B-NCT), and Gd-DTPA (Gd-NCT)

Poly-Ferrofluids for chemo- and radiation-therapy of cancer (fig.2d, 5d) and Magnetite cores for entrapping in magnetic liposomnes (fig.2c, 5c) were studied by unstained and magnetic electron microscopy, dynamic light scattering (M-DLS), SANS (ILL-D22) and (A)SAXS (ESRF-ID1: MD118). The commercial shell poly-Ferrofluids obtained by limited etching were disk-shaped (h=15 nm; d=50-100 nm) and consisted of dense iron oxide spheres embeded in disks of lower density. Material from double synthesis contained 3% Hafnium in the outer shell (ASAXS + XAS; analysis by L-edge shift)

Reversible formation of a magnetic superstructure from poly-Ferrofluids was observed at conditions equivalent to medical treatment by magnetic DLS and magnetic EM;. The dynamics has to be studied by time resolved methods, because the effect is important for the medial application, blood interaction.

Magnetic target liposomes containing magnetite cores (fig.2c, 5c) where analylized at the absorption L-edge in structure and target distribution by ASAXS at ESRF-ID1 (MD118) after loading with water soluble heavy metal targets (Gd-DTPA, Tm-DTPA, Lu-DTPA, Hf-DTPA, cis-Platinun) Prior to the ASAXS experiments the excess target outside of the liposomes was freshly removed by gel filtration chromatogrphy at the beamline (Sephadex G25m). Thus the L-edge (white line) XAS analysis yielded the entrapped target content, the ASAXS the target localization; both required for medical application (at K-edge). With magnetic Gd-liposomes the iron and gadolinium edges were observed in parallel. Target reference solutions (0.7-2 M) had to be diluted because of the very low transmission at the L-edge ("black"; white lines). With the Lanthanide-DTPA's in citrate, pH7.5 no interference with liposome structure up to 0.7 M was observed. By energy (transmission) Lutetium-DTPA was optimal.

ASAXS and time-resolved scattering are required for medically shure target nanoparticles

- 1. T. Nawroth, M. Rusp and R.P. May, Physica B 350, e635-638 (2004) "Magnetic liposomes and entrapping
- ne resolved neutr n scattering TR-SANS and electron mici 2.
- time resorved neuron scattering TresArx8 and receton microscopy T. Nawroth, K. Meesters, H. Decker, M. Rusp, G. Le Due, St. Corde, A. Bravin, H. Requardt, T. Brochard; ESRF experiment report MD163-1 (2005) "Imaging of imobilised magnetic target nanoparticles: liposomes and ferrofluids entrapping targets for magneto-photodynamic therapy of cancer M-PATY" T. Nawroth, R. Gebhardt, M. Rusp, I. Grillo, R.P. May, ILL experiment reports 8-03-413 & 9-10-661 (2004)
- Time re d neutron scattering of magnetic liposom es entrapping target
- "International Atomic Energy Agency IAEA, status report (2001) "Neutron Capture This report is sufficiently critical and actual, but limited on Boron therapy (B-NCT) re The rapy Acknowledgements

ESRF-experiments: LS1554, 1718, 1843; MD118, 128, 163; ILL-experiments: 8-03-413, 9-10-661; BMBF project 03-Na4-Mai (Nawroth) The target materials in biocompatible formulation LuDTPA (Lutevist), several Lanthanide-DTPA samples (Lanthavist), Boron-diol-esters and magnetic Ferrofluid nanoparticles were a gift of FerroMed (www.ferromed.de).